# BarbellTX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/barbelltx

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.barbelltx.com/
- Latest round: Angel (May 23, 2025)
- Investors on record: 2

## About

Founded in 2020 and headquartered in Shanghai, China, BarbellTX specializes in biopharmaceutical solutions. In May 2025, BarbellTX closed an angel+ funding led by Yongkan Investment, with participation from Frees Fund. BarbellTX specializes in innovative gene therapies aimed at enhancing patient care across their lifecycles. The company's core offerings focus on durable therapeutic solutions, enabling repeat administration to manage chronic health conditions and genetic disorders. BarbellTX leverages advanced biotechnological developments to provide treatments that improve health outcomes. BarbellTX generates revenue through partnerships with healthcare institutions and direct sales to clinics and hospitals. The company engages in business-to-business transactions, working with medical facilities to integrate its gene therapies into treatment protocols. Revenue is also supported by subscription agreements for ongoing product access and potential licensing of proprietary technology to other biotech firms. The angel+ funding will be allocated towards advancing the product pipeline and facilitating early clinical validation of its first product. The company aims to launch upcoming products designed to meet growing medical needs while expanding its market presence into Europe and North America by the end of 2025.

## Funding rounds

- Angel, May 23, 2025 — Yongkan Investment, Frees Fund

## Investors

- Yongkan Investment (https://capitalatlas.ai/funds/yongkan-investment) — Angel
- Frees Fund (https://capitalatlas.ai/funds/frees-fund) — Angel